Casopitant and GSK525060 pharmacokinetic parameters observed when casopitant is either administered on its own or together with rifampin
Data are mean ± S.D. or median (range) for tmax.
| Analyte | Treatmenta | AUC(0–t) | Cmax | tmax | t1/2 |
|---|---|---|---|---|---|
| ng · h/ml | ng/ml | h | h | ||
| Casopitant | A | 6570 ± 2180 | 847 ± 279 | 1.25 (0.53–6.00) | 19.2 ± 7.1 |
| B | 273 ± 127 | 93.2 ± 39.8 | 1.00 (0.50–2.05) | 6.45 ± 2.95 | |
| Ratio treatment B vs. Ab | 0.04e | 0.11 | |||
| GSK525060 | A | 5260 ± 1380 | 350 ± 110 | 2.00 (1.00–8.00) | 17.6 ± 7.0 |
| B | 311 ± 114 | 93.0 ± 32.2 | 1.26 (0.50–2.05) | 3.36 ± 1.12 | |
| Ratio treatment B vs. Ab | 0.06e | 0.26 |
↵a Treatment A = 150 mg of oral casopitant (n = 18). Treatment B = 150 mg of oral casopitant (day 8) + 600 mg of rifampin (q.d., days 1–9) (n = 16).
↵b Exposure ratios are given with two decimal places in tables, and with at least one decimal place in the text. Data from Johnson et al. (2010).
↵e Comparison based on the geometric mean of AUC(0–t).